Hims & Hers Health announced the launch of its Peptides+ platform on Wednesday, offering five compounded peptide and longevity treatments that are not FDA-approved [1]. The initial product offerings include Sermorelin (marketed for growth-hormone stimulation and anti-aging), Glutathione (promoted for anti-aging and athletic recovery), NAD+ (a coenzyme involved in cellular metabolism), Vitamin B-12 (for red blood cell production and nerve function), and L-carnitine (an amino acid derivative for fat metabolism) [1]. While none of these compounded products have FDA approval, Hims states they are "authorized by law and formulated by pharmacies that adhere to rigorous quality standards and are licensed and inspected by state boards of pharmacy" [1].
The company generated significant early interest in the offering, with more than 10,000 people signing up for an early access list launched in late October within just 15 days [1]. Hims plans to expand the platform over time with additional peptides including BPC-157 and TB-500, both unapproved compounds marketed for healing and tissue recovery, though the company notes that most research on these peptides has been conducted in animals rather than humans [1].
Critically, Hims' Chief Medical Officer Dr. Anant Vinjamoori acknowledged significant uncertainty regarding the efficacy and optimal use of these peptides, stating: "We don't have all of this data that we're used to having with compounds like this" [1]. To mitigate risks, the company will require patients to undergo health assessments with licensed providers trained in peptide therapies before receiving products, and will use its communication platform to monitor patient outcomes and adjust treatments as needed [1]. Vinjamoori emphasized the company's responsibility to "lead" in gathering data on these treatments, indicating Hims views itself as a research participant in an emerging market segment [1].
CONCLUSION
Hims & Hers is capitalizing on growing consumer interest in longevity and peptide therapies by launching a compounded treatment platform, though the company explicitly acknowledges limited clinical data on efficacy and safety. The strong early uptake (10,000+ signups in 15 days) suggests significant market demand, but the reliance on unapproved compounds and limited human research data presents regulatory and reputational risks that could impact the company's trajectory.